David A. Siegel Lumos Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Lumos Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 31,900 shares of LUMO stock, worth $72,413. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,900
Previous 28,300
12.72%
Holding current value
$72,413
Previous $89,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding LUMO
# of Institutions
42Shares Held
2.29MCall Options Held
0Put Options Held
0-
Wells Fargo & Company San Francisco, CA416KShares$943,3000.0% of portfolio
-
Goldman Sachs Group Inc New York, NY407KShares$923,0090.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA244KShares$554,0660.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny218KShares$494,8910.0% of portfolio
-
Acuitas Investments, LLC141KShares$319,3640.21% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $19.1M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...